Canada nguva 2022-01-24, RhoVac, kambani yemishonga yakanangana nebundu immunology, yakazivisa kuti patent yayo yekushandisa (No. 2710061) yekenza peptide vaccine RV001 ichabvumidzwa neCanadian Intellectual Property Office (CIPO).Kare, kambani iyi yakawana zvibvumirano zvine chekuita neRV001 muUnited States, Europe neJapan.Uku kupihwa patent kuchapa dziviriro yakafara yeRV001 mumisika mikuru uye kusimudza zvipingamupinyi zvekambani patent.
Kufanana neyakambopihwa patent application, patent iyi inovhara RV001 cancer yekudzivirira uye akasiyana ayo, pamwe nekushandiswa kwayo mukurapa/kudzivirira RhoC-inoratidza metastatic cancer.Pakati pavo, RhoC ndeye tumor-yakabatana antigen (TAA) iyo yakanyanyisa kuwedzeredza mumhando dzakasiyana dzebundu cell.Kana yangopihwa, patent ichapera muna 2028-12 uye inotarisirwa kuwedzerwa pakuwana Chitupa cheKuwedzera Dziviriro (CSP).
01 Onilcamotide
Onilcamotide mushonga wegomarara unosanganisira immunogenic peptides inotorwa kubva kuRas homologous nhengo yemhuri C (RhoC), iyo inogona kuiswa emulsified mune immune adjuvant montanide ISA-51, ine inogona immunomodulatory uye antitumor zviitiko.Subcutaneous manejimendi yeOnilcamotide inosimudzira mauto immune system kuti aise anosekesa uye cytotoxic T lymphocyte (CTL) mhinduro kuRhoC-inoratidza bundu masero, nekudaro achiradzika bundu masero.
2020-11, RV001 yakapihwa Fast Track kudomwa neFDA.
02 Miedzo yemakiriniki
Muna 2018, Phase I/IIa kiriniki yekuyedza yeOnilcamotide yekurapa cancer yeprostate yakabvumidzwa, uye varwere makumi maviri nemumwe vakanyoreswa.Mhedzisiro yacho yakaratidza kuti Onilcamotide yaive yakachengeteka uye yakatenderwa zvakanaka.Mukuwedzera, varwere vakagadzira mhinduro dzakasimba uye dzakasimba dzekudzivirira mushure mekurapwa.Muna 2021, kuteverwa kwezvidzidzo izvi gumi nepfumbamwe, makore matatu mushure mekupedzwa kurapwa neRhoVac, kwakaratidza kuti zvidzidzo izvi hazvina kuita metastases kana kugamuchira kumwe kurapwa uye vasina kukosha kwakakosha kweprostate-specific antigen (PSA)..Pakati peizvi, zvidzidzo zve16 zvakanga zvisina kuonekwa PSA, uye zvidzidzo zve3 zvaive zvishoma nezvishoma PSA kufambira mberi.PSA ipuroteni inogadzirwa neprostate gland uye inoshandiswa kuona mafambiro egomarara reprostate rinozivikanwa.
Muna 2019, iyo RV001 Phase IIb kiriniki yeBraVac (yakasarudzika, yakapetwa-bofu, inodzorwa neplacebo) yakatangwa kuti iongorore kushanda kwayo mukudzivirira kana kudzikisira kukura kwegomarara reprostate mushure mekuvhiyiwa/kuvheneka.Iyi IIb kiriniki yekuedza ndeyekune dzimwe nyika, yakawanda yekudzidza kunyoresa vanhu munyika 6 dzeEurope (Denmark, Finland, Sweden, Belgium, Germany, uye United Kingdom) uye United States.Mhosva yacho yakapedzisa kupinza varwere basa muna 2021-09, ine huwandu hwevanenge 175 vakanyoresa, uye ichapera muna 2022H1.Pamusoro pezvo, RhoVac inoronga kuita preclinical exploratory zvidzidzo zvine chinangwa chekupa humbowo hwekuwedzera kweRV001 muzviratidzo.
Pamusoro pezvo, komiti yekutarisa kuchengetedza yakaitawo ongororo yekuchengetedzwa kwechinguvana yeRV001 muna 2021-07, uye hapana zviitiko zvakashata zvisingatarisirwi zvakawanikwa, izvo zvaienderana nechikamu chekare I / II mhedzisiro yekiriniki.
Nguva yekutumira: Feb-17-2022